Search Results

<< Back Immunotherapy DLL3 DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms CAR T CHM-2101 CAR-T cell for GI Cancers IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Cancer Vaccine Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Immune Checkpoint Inhibitor Combination Studies IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC Oncolytic Virus SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)

<< Go back to the Podcast page EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) Download a Transcript of Part 1 >> Download a Transcript of Part 2 >> ABOUT THIS EPISODE In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. MEET TAYMEYAH AL-TOUBAH, MPH Taymeyah Al-Toubah is a clinical researcher, currently at Moffitt Cancer Center, who has been in the research field for 10 years. She began her career in 2013 while obtaining her bachelors degrees in biomedical sciences and psychology, working in pediatric and neonatal research at Johns Hopkins All Children’s Hospital. In 2016, she shifted her career focus to oncology, beginning with phase I trials and working in all solid tumors. She completed her Master of Public health in epidemiology in 2017 and focused her graduate thesis on neuroendocrine tumors. In 2018, she switched departments to focus exclusively on NETs. From 2018 – 2023, she was the primary NET coordinator in the GI department, managing all clinical trials while leading the GI team, managing the NET clinic coordination amongst the ancillary departments, and working on all retrospective and non-interventional NET research. She has worked on protocol development, database analysis, and manuscript writing, resulting in over 30 published manuscripts and presented her research at several national and international oncology and NET conferences, with oral abstracts at several ENETS and NANETS conferences. In April 2023, she formally transitioned to a new position as a project manager of the NET program where she will continue to mentor new coordinators, while working on protocol development and writing, manuscript writing, non-interventional clinical trials, and retrospective NET research. One of her first major projects will be to curate and develop a master database of all NET patients seen at her institution that will provide the basis for all future NET research to be published at Moffitt. She is currently on the board of one of the first NET patient advocacy groups in Florida (FLaNET Carcinoid Community), which kicked off alongside the Tampa Regional NANETS meeting in November 2022. She is an active member in NANETS on the Continuing Education and Symposium Planning committees. She plans to dedicate the remainder of her career to this disease and community. Her ultimate plan is to attend medical school, specialize in medical oncology, and continue to serve the academic NET community and patient base as a physician and clinical investigator. RESOURCES READ Glossary: Common Terms in Clinical Trials Navigating Clinical Trials: Expectations vs Realities - Slides from August 19, 2023 LACNETS Educational Event "How to Prepare for Clinical Trials" Info Sheet WATCH https://www.youtube.com/watch?v=CXW71vedhIw DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Back Lung/Bronchial NETs PRRT/RLT Trials 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE vs Everolimus in Lung NETs Immunotherapies DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms Targeted Therapies Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

<< Back Pancreatic NET (PNET) Insulinoma upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism PRRT/RLT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine (GEP-NETs) Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs COMPOSE (GEP-NETS) ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients Oral Treatment SWOG S2104: Adjuvant CAPTEM for High Risk pNET Belzutifan/MK-6482 in PNET + PPGL + VHL CDK4/6 Abemaciclib Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers SORENTO™: Subcutaneous Octreotide for GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) SORENTO™: Subcutaneous Octreotide for GEP-NETs STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Lu-177 DOTATATE + M3814 (Peposertib) in GEP-NETs << Back Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT04750954 DRUG/TREATMENT: lutetium Lu-177 dotatate in combination with M3814 (peposertib) PHASE: 1b STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=2pfbNMs9sZA Dr. Aman Chauhan discusses Lu-177 Dotatate + M3814 DESCRIPTION: This phase Ib trial is to find out the best dose, possible benefits and/or side effects of peposertib when given together with lutetium Lu-177 dotatate in treating patients with neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aman Chauhan, MD EMAIL: axc3268@med.miami.edu

CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors << Back CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy CLINICALTRIALS.GOV IDENTIFIER: NCT03375320 DRUG/TREATMENT: Cabozantinib PHASE: 3 STATUS: Closed SPONSOR: National Cancer Institute (NCI) Update - November 9, 2025 https://www.youtube.com/watch?v=balUaCFLceI Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Download the transcript here >>> Update - October 18, 2025 Exelixis Announces Positive Results for CABOMETYX® in Lung and Thymic Neuroendocrine Tumors At ESMO 2025, researchers reported that CABOMETYX® (cabozantinib) significantly delayed tumor growth in people with advanced lung or thymic neuroendocrine tumors—reducing the risk of disease progression or death by 81% compared to placebo. These results come from a subgroup of the phase 3 CABINET trial, which led to FDA and European approvals earlier this year for advanced pancreatic and extra-pancreatic NETs. Why this matters to patients: Lung and thymic NETs are rare and often have few treatment options. CABOMETYX offers a new targeted therapy that may help keep these tumors from growing. Read the full press release here >>> Update - March 26, 2025 A New Treatment Option has been FDA approved for those living with NET. For details, see the press release . UPDATE - September 16, 2024 On Sept 16, 2024, LACNETS interviewed incoming NANETS president, Dr. Jennifer Chan from Dana Farber Cancer Institute following her presentation on the updated, results of the CABINET trial at the medical and scientific meeting, ESMO (the European Society for Medical Oncology) Congress 2024 in Barcelona, Spain. The presentation was titled Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses. https://www.youtube.com/watch?v=4iWtw3qmrBs Watch our latest interview on Sept 16, 2024 with Dr. Jennifer Chan at ESMO (the European Society for Medical Oncology) Congress 2024 in Barcelona, Spain. For more information, read our blogpost: Positive Results of the Cabinet Trial Show Cabozantinib As a New Effective Treatment in Advanced Neuroendocrine Tumors . Read more in the latest NEJM article released Sept 16, 2024: Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. UPDATE - October 25, 2023 Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extra pancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future. Click here to read the detailed results of the CABINET trial here: Business Wire - "Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 " OncLive - "Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors" https://www.youtube.com/watch?v=VonfcmeellU Watch this exclusive video interview with Dr. Jennifer Chan at ESMO - European Society for Medical Oncology 2023 in Madrid, Spain. UPDATE - Aug 24, 2023 The Alliance for Clinical Trials in Oncology announced that the CABINET trial (NCT03375320) showed positive findings with cabozantinib having efficacy. The CABINET trial is a phase 3 randomized, double-blinded study evaluating cabozantinib compared with placebo in patients with advanced pancreatic neuroendocrine tumors (PNET) or advanced extra-pancreatic neuroendocrine tumors (carcinoid tumors) who experienced progression after prior systemic therapy. The trial is now being stopped early. It will be unblinded, meaning the patients will find out if they have been receiving placebo and those who have will have the possibility of receiving cabozantinib. The findings will be discussed with the U.S. Food and Drug Administration. Detailed results from the trial will be presented at an upcoming scientific meeting. To read the announcement, go to https://bit.ly/A021602-Interim or https://www.onclive.com/view/cabozantinib-efficacy-prompts-cabinet-trial-unblinding-in-advanced-pancreatic-and-extra-pancreatic-nets. https://www.youtube.com/watch?v=2H_SChk3gxw Dr. Jennifer Chan Discusses CABINET: Cabozantinib DESCRIPTION: This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors that, when blocked, may slow tumor growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Jennifer A Chan, MD, MPH Alliance for Clinical Trials in Oncology and National Cancer Institute (NCI)

Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC << Back A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab IDENTIFIER ( ClinicalTrials.gov ) : NCT05142696 DRUG/TREATMENT : LUTATHERA (Lu-177 Dotatate) + Carboplatin, Etoposide, and Atezolizumab PHASE : 1b / 2 STATUS : Recruiting SPONSOR : Novartis Pharmaceuticals DESCRIPTION: https://www.youtube.com/watch?v=0h8ye62LDT0 Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC ." Recorded: June 20, 2024 This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab. The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Novartis Pharmaceuticals EMAIL: novartis.email@novartis.com PHONE: 1-888-669-6682 RELATED RESOURCES : Clinical Trials Using Lutetium Lu 177 Dotatate - NCI https://www.youtube.com/watch?v=oCHpfmQLeJM "High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" with Aman Chauhan, MD

<< Go back to the Podcast page EPISODE 52 - Spotlight on Genetic Counselors Download a Transcript of this Episode >>> ABOUT THIS EPISODE Who is a genetic counselor, and who should see one? How do they fit into the neuroendocrine cancer care team? In this episode, Samantha Greenberg, PhD, MS, MPH, CGC, Director of the UT Southwestern Genetic Counseling Program, demystifies genetic counseling and testing for NET patients and their families. She explains what to expect before, during, and after a consultation—and how results can impact care, family members, and future planning. TOP TEN QUESTIONS Role & Training 1. What is a genetic counselor? What training is required? What’s your role in the care team? Genetic Counseling & NETs 2. How are genetic counselors involved in NET care? 3. Who should get genetic testing? Do all NET patients need it? What if more than one family member has NET? Do you also see family members without a diagnosis? 4. How does one’s age play a role? Testing Basics 5. Genetic vs. genomic vs. NGS—what are these terms? How do patients know they’re getting the right test? 6. Walk us through a genetic counseling consultation—before, during, after. Results & Implications 7. What if the results are positive? How do you guide patients and families? What if the results are negative or inconclusive? How accurate are tests? 8. What is a “variant of unknown significance”?9. Can environment or toxins cause hereditary mutations? Practical Guidance 10. How can patients find the right genetic counselor? Do they need to be someone who specializes in neuroendocrine cancer? MEET SAMANTHA GREENBERG Samantha Greenberg, PhD, MS, MPH, CGC Pronouns: she/her Director, UT Southwestern Genetic Counseling Program Assistant Professor School of Health Professions Samantha Greenberg is the founding program director of the UT Southwestern Genetic Counseling Training Program. She received her Master of Science degree in genetic counseling and public health from the University of Michigan after teaching middle school science with Teach For America in Tulsa, Oklahoma. She recently completed her Ph.D. at the University of Utah. As a cancer genetic counselor, Greenberg has provided clinical care across a variety of indications and facilitated the development of multidisciplinary teams and genetics clinics for patients with prostate cancer, von Hippel-Lindau syndrome, and paraganglioma/pheochromocytoma. She is the co-director of the paraganglioma program at UT Southwestern, which recently received a Center of Excellence designation from Pheo Para Alliance. Her passion for raising awareness on the genetics of neuroendocrine tumors stems from working with patients and a curiosity for how to optimize identification of patients with hereditary risk. RESOURCES Watch https://www.youtube.com/watch?v=VWMdD5LJAFo Genetics of NET: Do I Need Genetic Testing with Samantha Greenberg (Feb 2023) https://www.youtube.com/watch?v=wgEoFAQ7lp8 Deciphering Genetics & Genomics in Neuroendocrine Cancers with Dr. Kimberly Perez (Feb 2025) EXPLORE FindaGeneticCounselor.com https://pheopara.org/ DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

225Ac-ABD147 to Establish Optimal Dose in SCLC and LCNEC << Back A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy IDENTIFIER ( ClinicalTrials.gov ) : NCT06736418 DRUG/TREATMENT : 225Ac-ABD147 PHASE : 1A/B STATUS : Recruiting SPONSOR : A bdera Therapeutics Inc. https://www.youtube.com/watch?v=PDR0flgpAXE DLL-3-RLT Presentation Slides .pdf Download PDF • 863KB DESCRIPTION: This is an open-label, Phase 1a/1b, first-in-human study testing a new targeted treatment called 225Ac-ABD147 for people with locally advanced or metastatic small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung. All participants must have previously received platinum-based chemotherapy. What is 225Ac-ABD147? 225Ac-ABD147 is a DLL3-targeting antibody fragment, a small, engineered piece of an antibody that targets cancer cells with a marker called delta-like ligand 3 (DLL3) . It is attached to a special linker-chelator that holds a radioactive particle ( Actinium-225 ) so that a precise dose of radiation can be delivered directly to DLL3-positive cancer cells. The study has two parts: Phase 1a and Phase 1b . Phase 1a: Safety, Dosing & Early Signals Phase 1a is designed to understand: Safety and side effects How the drug moves through the body (PK and biodistribution) Early signs of effectiveness The safest and most appropriate dose levels A small group of participants will also receive an experimental imaging agent, 111In-ABD147 , to help researchers see how the treatment travels and where it binds in the body. Phase 1b: Expanded Testing at Selected Doses Phase 1b uses the dose levels identified in Phase 1a to further evaluate: Safety How well the treatment works for SCLC and LCNEC This phase helps researchers better understand the potential benefit of 225Ac-ABD147 in these cancers. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Abdera Therapeutics Inc. EMAIL: AbderaClinicalTrials@abderatx.com PHONE: 1 650-434-4093 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

Lu-177 DOTATATE + Olaparib in GEP-NETs << Back Lu-177-DOTATATE in Combination With Olaparib in Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) CLINICALTRIALS.GOV IDENTIFIER: NCT04086485 DRUG/TREATMENT: Lu-177 DOTATATE + OLAPARIB PHASE I / II STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=CC2NXP21R24 Dr. Del Rivero discusses Lu177-Dotatate + OLAPARIB DESCRIPTION: This phase 1-2 trial tests Lu-177-DOTATATE (Lutathera) in combination With olaparib (PARP inhibitor) in inoperable gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). The objective is to learn if people with certain neuroendocrine tumors can take a combination of 2 drugs, Lu-177 DOTATATE and Olaparib, without having severe side effects, and if this treatment makes the tumors shrink. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Frank Lin, MD CONTACT: National Cancer Institute Joy Zou, RN EMAIL: joy.zou@nih.gov PHONE: 240-760-6153

<< Back NIH/NCI Natural History Study for Neuroendocrine Neoplasms Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

< Go Back to the Resource Guide CARCINOID HEART DISEASE WATCH https://www.youtube.com/watch?v=jU1HE38G8JQ Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. https://www.youtube.com/watch?v=DcewKhYm8uY Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. https://www.youtube.com/watch?v=Y5PGL8-kFR4 Guests: Juan A. Crestanello, MD and Thor R. Halfdanarson, MD Host: S. Allen Luis, MBBS, PhD Join Mayo Clinic Cardiologist S. Allen Luis, M.B.B.S., Ph.D., surgeon Juan A. Crestanello, M.D. and oncologist Thor R. Halfdanarson, M.D. for up-to-date knowledge and information on Carcinoid Heart Disease. Recognize the natural history of patients with carcinoid heart disease. Identify treatment strategies for patients with metastatic neuroendocrine tumors and its impact on the heart Identify the medical and surgical treatment of patients with carcinoid heart disease. PATIENT STORIES https://www.youtube.com/watch?v=4TU4WMGd4lc Watch Jesse & Ellen share their story of living with Carcinoid Heart Disease. https://www.youtube.com/watch?list=PLPAgUIq-85n9gMW_Majhts3lqzoIaIQbx&v=tMBDhGT5lmI Watch Gwendolyn’s story of living with metastatic NET and Carcinoid Heart Disease. LISTEN What is Carcinoid Heart Disease (CHD)? Which NET patients develop CHD? Retired cardiologist and carcinoid heart disease specialist Dr. Jerome Zacks provides an overview of CHD and describes the appropriate screening, diagnosis, and treatment. Visit the Podcast Episode 43 webpage for more information and resources. READ Davar et al (2017). "Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement". J Am Coll Cardiol.; 69 (10) 1288–1304 Jin et al (2021). "Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management". Cardiology;146:65–73 Ram et al (2019). "Carcinoid Heart Disease:Review of Current Knowledge". Texas Heart Institute Journal February 2019, Vol. 46, No. 1